We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dental implants in individuals living with HIV‐1: Results from a prospective study in patients undergoing highly active antiretroviral therapy.
- Authors
Vidal, Fábio; Peres, Rafael Vidal; de Souza, Rodrigo Carvalho; Gonçalves, Cristiane; Pavan, Priscila; Gonçalves, Lucio Souza
- Abstract
Objective: To assess survival and success rates of dental implants and the occurrence of peri‐implant diseases (mucositis/peri‐implantitis) in HIV‐1‐infected individuals. Material and methods: In this prospective study, 13 HIV‐1‐infected individuals undergoing highly active antiretroviral therapy (with undetectable plasma HIV RNA levels, and CD4+ T cells > 350/mm3) were followed after implant placement, as well as 13 non‐HIV‐1‐infected matched controls. Patients enrolled in this study were followed up to 120 months (mean = 40.6 months; standard deviation = 22.2; range 18 –120 months). Twenty‐five implants were placed in pristine healed sites for each group and bone augmentation procedures, when needed, were done only for contour augmentation. Patients were enrolled in a strict periodontal/peri‐implant supportive therapy protocol with three recalls per year. The two groups were compared regarding subject‐level characteristics (age, gender, smoking, diabetes) and implant‐level characteristics (marginal bone level, peri‐implant health status). Results: All the implants healed uneventfully and reached 100% survival rates (after at least 18 months) in both groups. There were no significant differences between groups for peri‐implant diseases (mucositis/peri‐implantitis) and for all subject‐level co‐variables (p >.05). Only the variables dental implant prosthesis type (DIPT) (p =.021, d =.86) and follow up (p =.011, d =.77) showed statistically significant differences between groups. Conclusion: The findings suggest that well‐controlled HIV‐1‐infected individuals are eligible to undergo implant therapy, achieving survival and success rates comparable to non‐HIV‐1‐infected controls.
- Subjects
HIGHLY active antiretroviral therapy; CD4 lymphocyte count; DENTAL implants; DENTURES; HIV; LONGITUDINAL method
- Publication
Special Care in Dentistry, 2022, Vol 42, Issue 2, p112
- ISSN
0275-1879
- Publication type
Article
- DOI
10.1111/scd.12646